Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2" Bayer Terminated BAY 80-6946/Copanlisib 3 BAY 80-6946 / 17322 KAUH-J
A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study McMaster University Completed haemagglutinin (HA)/Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) 3 Version date Sep-3-2013 KKUH
A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy Roche Terminated Bevacizumab+ Capecitabine 3 MO22223 KAH & OC
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission National Cancer Institution Ongoing RITUXIMAB 3 EA4151 King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer NRG Oncology King Faisal Specialist Hospital & Research Center Ongoing CISPLATIN (CISPLATYL ) 2 NRG-HN002 KFSH & RC-R
"A Randomized controlled Trial of Influenza Vaccine to Reduce Adverse Vascular Events" McMaster University Ongoing Vaxigrip 3 version 2 KKUH
"A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack [THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death] " AstraZeneca Completed Ticagrelor 3 D5134C00003 KFMC
A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) Astrazeneca Ongoing Ticagrelor 3 D5136C00009 KFMC
A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. Actelion Pharmaceuticals Ltd Completed Macitentan (ACT-064992, Opsumit ®) 3 67896062CTP3001 King Fahad Medical City (Riyadh)
"A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity of Arabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56 Years and Above in Saudi Arabia" Arabio Completed Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen) 3b ARA/001/16 KKUH
View 291 - 300 From 720